ArticleToxins2020
Anti-Biofilm Activity of the Fungal Phytotoxin Sphaeropsidin A Against Clinical Isolates of Antibiotic-Resistant Bacteria.
Article in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Discovery of a dimeric isopimarane derivative by reexploring a labdane-related diterpenoid biosynthetic gene cluster in Aspergillus nidulans.Microbial cell factories · 2026Article
- Activities of fungal metabolites sphaeropsidin A and B to fight against canine coronavirus.Veterinary research communications · 2026Article
- Secondary Metabolites from Diaporthe eres SK3, an Endophytic Fungus of Sellaginella kraussiana Sw. Collected from the Northeast Indian Hills, Exhibits Potential in Vitro Bioactivities.Current microbiology · 2026Article
- Structural Features and In Vitro Antiviral Activities of Fungal Metabolites Sphaeropsidins A and B Against Bovine Coronavirus.International journal of molecular sciences · 2025Article
- Yeast-derived glycolipids disrupt Candida biofilm and inhibit expression of genes in cell adhesion.Scientific reports · 2025Article
- Bioactivities of secondary metabolites of two actinomycetes Streptomyces parvulus GloL3, and Streptomyces lienomycini SK5, endophytes of two Indian medicinal herbs- Globba marantina L. and Selaginella kraussiana (Kunze) A. Braun.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Sphaeropsidin A Loaded in Liposomes to Reduce Its Cytotoxicity and Preserve Antifungal Activity AgainstMolecules (Basel, Switzerland) · 2024Article
- Advances on anticancer fungal metabolites: sources, chemical and biological activities in the last decade (2012-2023).Natural products and bioprospecting · 2024Article
- Endophytes: a uniquely tailored source of potential antibiotic adjuvants.Archives of microbiology · 2024Review
- Topical antifungal keratitis therapeutic potential ofFrontiers in microbiology · 2024Review
- Antifungal activity of cyclopaldic acid from Antarctic3 Biotech · 2023Article
- Comparative Analysis of Secondary Metabolites inMolecules (Basel, Switzerland) · 2023Article
- Natural Strategies as Potential Weapons against Bacterial Biofilms.Life (Basel, Switzerland) · 2022Review
- Bioactive Lipodepsipeptides Produced by Bacteria and Fungi.International journal of molecular sciences · 2022Review
- The Assignment of the Absolute Configuration of Non-Cyclic Sesquiterpenes by Vibrational and Electronic Circular Dichroism: The Example ofBiomolecules · 2021Article
- Sphaeropsidin A: A Pimarane Diterpene with Interesting Biological Activities and Promising Practical Applications.Chembiochem : a European journal of chemical biology · 2021Review
- Diterpenes/Diterpenoids and Their Derivatives as Potential Bioactive Leads against Dengue Virus: A Computational and Network Pharmacology Study.Molecules (Basel, Switzerland) · 2021Article
- Antimicrobial Activity of a Lipidated Temporin L Analogue against Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- In Vitro Antibacterial, Antifungal, Nematocidal and Growth Promoting Activities ofJournal of fungi (Basel, Switzerland) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Many pathogens involved in human infection have rapidly increased their antibiotic resistance, reducing the effectiveness of therapies in recent decades. Most of them can form biofilms and effective drugs are not available to treat these formations. Natural products could represent an efficient solution in discovering and developing new drugs to overcome antimicrobial resistance and treat biofilm-related infections. In this study, 20 secondary metabolites produced by pathogenic fungi of forest plants and belonging to diverse classes of naturally occurring compounds were evaluated for the first time against clinical isolates of antibiotic-resistant Gram-negative and Gram-positive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.